![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, the companies are developing antisense oligonucleotides (ASOs) leveraging the powerful Creyon™ Platform for multiple neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cajal Neuroscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 01, 2024
Details:
The proceeds of financing will support continued optimization of the Creyon Platform, expanding the team, and laying the foundations for a diverse internal pipeline. Creyon’s drug development platform creates purpose-built data sets orders of efficient than current approaches.
Lead Product(s): Oligonucleotide-based Medicine
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: DCVC Bio
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 08, 2022